Cryptosporidium parvum oocysts (ABO809)

ABO809 is a standardized preparation of *Cryptosporidium parvum* oocysts used as a challenge agent in Controlled Human Infection Models (CHIM). In clinical research, such as studies conducted by Novartis, ABO809 is administered orally to healthy volunteers to induce a controlled infection of cryptosporidiosis. This model is utilized to evaluate the efficacy, safety, and tolerability of new antiparasitic drug candidates, such as EDI048, by providing a predictable clinical environment to observe disease progression and treatment response. The use of ABO809 is a critical step in the development of therapies for cryptosporidiosis, particularly for pediatric populations in resource-limited settings where the parasite is endemic.

Other names

Cryptosporidium parvum oocystsABO809 oral suspensionABO-809 oral suspensionABO 809 oral suspension